Female Breast Cancer Clinical Trial
Official title:
Efficacy of Endocrine Therapy Compared to Chemotherapy as a Neoadjuvant Treatment for Patients With Hormone Receptor-positive and HER2-negative Breast Cancer.
Eligible patients will be divided into two groups; one will receive neoadjuvant endocrine therapy and the other one will receive neoadjuvant chemotherapy.
Patients will be randomized into two groups: The first group (Arm A) will receive NCT; (Any approved Chemotherapy protocol by guidelines. The second group(Arm B) will receive NET; GnRH analog Goserelin acetate 3.6 mg every 4 weeks with tamoxifen 20 mg daily for premenopausal patients or an aromatase inhibitor for postmenopausal patients. - Before and during treatments (every 3 weeks for the NCT group, and every 4 weeks for the NET group), the clinical assessment will be performed for all patients. - All patients will undergo breast magnetic resonance imaging (MRI) before the start of treatment, after 12 weeks (3 months) of treatment, and after the end of treatment before surgery. - We will determine the objective tumor response with every measurement method and assess the response according to the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. - Treatment will be continued for 19-21 weeks before surgery for the chemotherapy group and 24 weeks for the endocrine therapy group. - Ki-67 will be assessed using a sample of the core biopsy before treatment and a surgery specimen after treatment. - Adverse events will be recorded at every patient visit and will be assessed according to the Common Terminology Criteria for Adverse Events Version 5.0. - Surgery will be performed between the 24th and 26th week. - Arm B Patients who will develop PD or SD after 6 months of treatment will be shifted to arm A. The primary endpoint will be; - The clinical response rate at the end of neoadjuvant treatment, as will be determined using caliper and MRI measurements. - A clinical response included either a complete response (CR), a partial response (PR), Progressive Disease (PD), or Stable Disease (SD) according to the (RECIST) version 1.1. Secondary endpoints will be; - The rate of pathological complete response (pCR). - The rate of breast conservation surgery. - Ki-67 changes. - The length of time to maximum response within a treatment period. - The Adverse events associated with each treatment arm. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02480933 -
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
|
N/A | |
Completed |
NCT05000502 -
Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations
|
N/A | |
Not yet recruiting |
NCT04863833 -
Tomosymthesis for Breast Mass Lesion Characterization
|
||
Withdrawn |
NCT06145399 -
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
|
Early Phase 1 | |
Suspended |
NCT01320488 -
Breast Cancer in Young Women: Is it Different?
|
N/A | |
Recruiting |
NCT02089854 -
Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
|
Phase 4 | |
Active, not recruiting |
NCT01741883 -
Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients
|
N/A | |
Recruiting |
NCT06144164 -
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
|
Phase 3 | |
Recruiting |
NCT06331793 -
Pulsed Electromagnetic Fields for Analgesia Post Mastectomy
|
N/A | |
Recruiting |
NCT05439499 -
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
|
Phase 3 | |
Terminated |
NCT03836872 -
Acupuncture for Joint Symptoms in Patients With Breast Cancer
|
N/A | |
Recruiting |
NCT06332976 -
PrefeRences And ChemoTherapy In Breast Cancer patiEnts
|
||
Completed |
NCT01671319 -
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06092892 -
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
|
Phase 2 | |
Recruiting |
NCT05586256 -
Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
|
||
Not yet recruiting |
NCT03153631 -
Female Sexual Dysfunction in Breast Cancer Patients
|
N/A | |
Active, not recruiting |
NCT03059875 -
Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)
|
N/A | |
Active, not recruiting |
NCT02088710 -
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
|
N/A | |
Terminated |
NCT01083641 -
Estrogen for Triple Negative Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05374161 -
An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain
|
N/A |